Future of £58m Bristol research centre in question following deal

Plans for a new £58m research centre in Bristol are reportedly in question after an acquisition deal.

Wiltshire inhaler firm Vectura, which was behind the proposals, was snapped up last week by US manufacturer Molex - the parent firm of contract development organisation Phillips Medisize.

It acquired the Chippenham-headquartered respiratory medicines business from tobacco giant Philip Morris International for a knock-down price of £150m ($198m).

The Marlboro cigarette maker announced the sale of Vectura last September, three years after buying the business for more than £1bn. The acquisition deal in 2021 was criticised at the time because Vectura's products are used to treat lung conditions.

In 2022, Vectura was Next Page

Recommend